REFERENCES
1. Ferlay, J., et al., Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019.144 (8): p. 1941-1953.
2. Strongman, H., et al., Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet, 2019. 394 (10203): p. 1041-1054.
3. Koene, R.J., et al., Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation, 2016. 133 (11): p. 1104-14.
4. Curigliano, G., et al., Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin, 2016. 66 (4): p. 309-25.
5. Cardinale, D., et al., Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol, 2010. 55 (3): p. 213-20.
6. Romond, E.H., et al., Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 2012. 30 (31): p. 3792-9.
7. Florescu, M., et al., Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr, 2014. 27 (1): p. 83-92.
8. Negishi, K., et al., Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr, 2013. 26 (5): p. 493-8.
9. Zamorano, J.L., et al., 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J, 2016. 37 (36): p. 2768-2801.
10. Zornoff, L.A., et al., Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol, 2002. 39 (9): p. 1450-5.
11. Larose, E., et al., Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J Am Coll Cardiol, 2007. 49 (8): p. 855-62.
12. Motoki, H., et al., Right ventricular global longitudinal strain provides prognostic value incremental to left ventricular ejection fraction in patients with heart failure. J Am Soc Echocardiogr, 2014. 27 (7): p. 726-32.
13. Ylanen, K., et al., Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol, 2013.61 (14): p. 1539-47.
14. Medvedofsky, D., et al., Novel Approach to Three-Dimensional Echocardiographic Quantification of Right Ventricular Volumes and Function from Focused Views. J Am Soc Echocardiogr, 2015.28 (10): p. 1222-31.
15. Nagata, Y., et al., Prognostic Value of Right Ventricular Ejection Fraction Assessed by Transthoracic 3D Echocardiography. Circ Cardiovasc Imaging, 2017. 10 (2).
16. Grapsa, J., et al., Right ventricular remodelling in pulmonary arterial hypertension with three-dimensional echocardiography: comparison with cardiac magnetic resonance imaging. Eur J Echocardiogr, 2010. 11 (1): p. 64-73.
17. Muraru, D., et al., New speckle-tracking algorithm for right ventricular volume analysis from three-dimensional echocardiographic data sets: validation with cardiac magnetic resonance and comparison with the previous analysis tool. Eur Heart J Cardiovasc Imaging, 2016.17 (11): p. 1279-1289.
18. Zhao, R., et al., Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography. JACC: CardioOncology, 2020. 2 (1): p. 13-22.
19. Rudski, L.G., et al., Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr, 2010. 23 (7): p. 685-713; quiz 786-8.
20. Kang, Y., et al., Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail, 2014. 16 (3): p. 300-8.
21. Khouri, M.G., et al., Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res Treat, 2014. 143 (3): p. 531-9.
22. Narayan, H.K., et al., Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.Circulation, 2017. 135 (15): p. 1397-1412.
23. Swain, S.M., F.S. Whaley, and M.S. Ewer, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 2003. 97 (11): p. 2869-79.
24. Stopeck, A.T., et al., A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood, 2012.120 (6): p. 1210-7.
25. Goldberg, M.A., et al., Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood, 1986. 68 (5): p. 1114-8.
26. Ho, E., et al., Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart, 2010. 96 (9): p. 701-7.
27. Thavendiranathan, P., et al., Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol, 2013.61 (1): p. 77-84.
28. Perel, R.D., R.E. Slaughter, and W.E. Strugnell,Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing’s sarcoma. J Cardiovasc Magn Reson, 2006. 8 (6): p. 789-91.
29. Thavendiranathan, P., et al., Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol, 2014. 63 (25 Pt A): p. 2751-68.
30. Smiseth, O.A., et al., Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J, 2016. 37 (15): p. 1196-207.
31. Simon, M.A., Assessment and treatment of right ventricular failure. Nat Rev Cardiol, 2013. 10 (4): p. 204-18.
32. Gulati, A., et al., The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation, 2013. 128 (15): p. 1623-33.
33. Christiansen, J.R., et al., Right ventricular function in long-term adult survivors of childhood lymphoma and acute lymphoblastic leukaemia. Eur Heart J Cardiovasc Imaging, 2016. 17 (7): p. 735-41.
34. Kocabas, A., et al., Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles. Pediatr Cardiol, 2014.35 (1): p. 82-8.
35. Skali, H., et al., Prognostic use of echocardiography 1 year after a myocardial infarction. Am Heart J, 2005. 150 (4): p. 743-9.
Figure Legends
Figure 1: Flowchart detailing patient selection.
Figure 2: ROC curves for 3D Echocardiographic Parameters in Predicting Later CAEs. (A) ROC curve analysis of LVGLS and RVEF respectively. The area under the curve (AUC) of LVGLS was 0.787 (95% CI, 0.666-0.908; P < .0001) (blue line) and the AUC of RVEF was 0.811 (95% CI, 0.712-0.910; P < .0001) (green line). (B) ROC curve analysis of combined LVGLS and RVEF (curve). When LVGLS and RVEF were combined in the ROC curve analysis, the sensitivity increased to 88.9%, the specificity was 82.1%, and the AUC increased to 0.882.
Figure 3: CAEs-free survival according to RVEF. Kaplan-Meier curves depicting CAEs-free survival in patients with RVEF above or below the absolute value of 46.33 %. Patients. *P =0.007.
Figure 4: Stepwise addition of left ventricular RVEF to GLS. On multivariate stepwise block analysis, adding RVEF to GLS gives significant additional prognostic value.
Figure 1